Dr Chauhan on Oncolytic Virus SVV-001 Plus Ipi/Nivo in Neuroendocrine Cancers

Dr. Aman Chauhan discusses a new clinical approach for treating neuroendocrine cancers using intralesional injections of the Seneca Valley virus combined with immunotherapy. This method aims to overcome the limitations of previous intravenous delivery attempts that were neutralized by the immune system.
Why it matters
Refining drug delivery methods for oncolytic viruses could significantly improve outcomes for patients with aggressive, hard-to-treat cancers.
Aman Chauhan, MD, discusses a first-in-human study of intratumoral Seneca Valley virus (SVV-001) combined with ipilimumab (Yervoy) and nivolumab (Opdivo) in patients with neuroendocrine cancer. In this interview from the 2026 North American Neuroendocrine Tumor Society (NANETS) Symposium, he explains why earlier intravenous studies of this oncolytic virus failed to show benefit, and how a change in the route of administration reopened the question.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in